Registered user of Farmavita.Net is looking for EU CTD Dossier with supply for GOSERELIN 3.6 mg subcutaneous implant. Product is sought for non-EU markets, where data exclusivity and patents are not in force.
Goserelin Acetate is an injectable gonadotropin releasing hormone super-agonist (GnRH agonist) also known as an LHRH agonist. It stops the production of sex hormones (testosterone and oestrogen). It was first launched in 1987 and is currently the second-largest selling GnRH analogue in the world. It is currently available in more than one hundred markets.
Goserelin 3.6 mg subcutaneous monthly biodegradable implant was first approved by the FDA on November 3, 1989 for treatment of prostate cancer, a 10.8 mg subcutaneous 3-month biodegradable implant and other indications were subsequently approved.
Offer is valid subject to confirmation of patent non infringement status of product. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights. Farmavita.Net is not owner of offered products/licenses and do not take any liability related to them. However, as the licensing agent we do our best to facilitate that closed licensing agreements are made on mutual benefit of contracting parties and without infringement of intellectual property of third parties.
|Pharma licensing||In-licensing (demand)|